Previous 10 | Next 10 |
There is more than one way to burn a book. And the world is full of people running about with lit matches ."― Ray Bradbury Today, we take an in-depth look at an intriguing ' Tier 4 ' concern. Like most small caps it was crushed in the COVID-19 meltdown, but has had a nice rally i...
Alnylam Pharmaceuticals (NASDAQ: ALNY) and Vir Biotechnology (NASDAQ: VIR) show no signs of slowing despite the current economic climate. These well-capitalized biotechs have ambitious plans to develop an array of innovative medicines. The companies recently banded together to ...
Biotech has held up surprisingly well in this market downturn, more or less tracking the S&P, but Alnylam ( ALNY ) has managed to outperform on a relative basis – showing only a small year-to-date decline. I’d like to believe that’s a recognition of the companyȁ...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) will collaborate with Dicerna Pharmaceuticals (NASDAQ: DRNA ) to investigate RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease , a relatively rare inherited disorder caused by the abnormally low productio...
- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization - - Companies Complet...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved induc...
— Preliminary Interim Data Show Normalization or Near-Normalization of Oxalate Levels in First Subset of Four Patients — — Nedosiran Multidose Data to Be Presented at OxalEurope Meeting Now Rescheduled to June 16, 2020 — Dicerna Pharmaceuticals, Inc. ...
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today provided an overview of its response to the COVID-19 pandemic and an update on business continuity and clinical ...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $200 (93% upside) price target at Berenberg. More news on: Summit Therapeutics plc, SpringWorks Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...